Evogene Files Annual Report for the Year Ended December 31, 2020

Rhea-AI Summary

Evogene Ltd. (NASDAQ: EVGN) has filed its annual report on Form 20-F for the fiscal year ending December 31, 2020, with the SEC. The report includes audited consolidated financial statements and is accessible on the SEC's website and Evogene's investor relations page. The company focuses on computational biology to advance product discovery in multiple life sciences, including human health and agriculture, utilizing its Computational Predictive Biology (CPB) platform. Shareholders can request a hard copy of the report.

Positive

• Evogene utilizes its Computational Predictive Biology (CPB) platform to discover and develop life-science products.
• The company is advancing product pipelines in diverse areas: therapeutics, medical cannabis, ag-biologicals, ag-chemicals, and ag-solutions.

Negative

• None.

REHOVOT, Israel, April 2, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020 with the U.S. Securities and Exchange Commission (the "SEC").

The annual report, which contains the Company's audited consolidated financial statements, can be accessed on the SEC website at http://www.sec.gov/ as well as via the Company's website at http://www.evogene.com/investor-relations. The Company will deliver a hard copy of its annual report, including its complete audited consolidated financial statements, free of charge, to its shareholders upon request to the Company Media Contact: ir@evogene.com.

About Evogene Ltd.:

Evogene (NASDAQ: EVGN), (TASE: EVGN) is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform.  The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements.  Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., and ag-solutions for castor oil production through Casterra Ltd.  For more information, please visit www.evogene.com.

Evogene Investor Contact:

Aviva Banczewski / Rivka Neufeld
Investor Relations and Public Relations Manager
E: IR@evogene.com  
T: +972-8-931-1900

US Investor Relations:

Joseph Green
Edison Group
E: jgreen@edisongroup.com  
T: +1 646-653-7030

Laine Yonker
Edison Group
E: lyonker@edisongroup.com  
T: +1 646-653-7035

Logo - https://mma.prnewswire.com/media/890385/Evogene_Logo.jpg

 

View original content:http://www.prnewswire.com/news-releases/evogene-files-annual-report-for-the-year-ended-december-31-2020-301261549.html

SOURCE Evogene Ltd

FAQ

What is Evogene's fiscal year 2020 annual report filing date?

Evogene filed its annual report on Form 20-F for the fiscal year ended December 31, 2020, on April 2, 2021.

Where can I access Evogene's annual report?

Evogene's annual report can be accessed on the SEC website and through their investor relations page at www.evogene.com.

What does Evogene focus on in its business operations?

Evogene specializes in computational biology, focusing on product discovery in sectors like human health and agriculture.

How can shareholders obtain a copy of Evogene's annual report?

Shareholders can request a hard copy of the annual report, including audited financial statements, from the company.